gastrointestinal excretion and a predictable relationship between pharmocokinetic and pharmacodynamic.

SUMMARY OF THE PRESENT INVENTION

The present invention provides the use of (2R,3R)-2-(3-carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl) benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in non-ST elevation myocardial infarction, said treatment comprising administering a therapeutically effective amount of (2R,3R)-2-(3-Carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl) benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof to a human patient, who is elderly or shows renal insufficiency or has low body weight or is elderly and shows renal insufficiency or is elderly and has low body weight or is elderly, shows renal insufficiency and has low body weight.

In one aspect, there is provided the use of (2R,3R)-2-(3-carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl) benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of non-ST elevation myocardial infarction, wherein the medicament is to be administered to a human patient, who is older than 65.

DETAILED DESCRIPTION OF THE INVENTION

The invention therefore provides the use of (2R,3R)-2-(3-carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl) benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in non-ST elevation myocardial infarction, said treatment comprising administering a therapeutically effective amount of (2R,3R)-2-(3-Carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl) benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof to a human patient, who is older than 65.

Terms used herein have the meanings defined in this specification.

"Elderly human patient" refers to patients beyond 65 years of age. A further group refers to patients from 65 to 75 or patients beyond 75 of age.